Log in automatically

Log in | New user?


Lundbeck acquires European commercialization rights for Flurizan® from Myriad, USA - a new drug in..
                   
euroinvestor.co.uk     22-May-2008            

H. Lundbeck A/S and Myriad Genetics, Inc. today announced that Lundbeck has acquired European commercialization rights to Myriad's Flurizan® (tarenflurbil). Flurizan® might have the potential to delay disability in patients suffering from Alzheimer's disease. Myriad and Lundbeck have entered into...


Full Coverage:

                   

Myriad Making Good Deals (at Motley Fool)

yahoo.com     23-May-2008          

By Brian Lawler May 23, 2008 Comments (0) Some drug deals are better than others. Yesterday, Rule Breakers pick Myriad Genetics (Nasdaq: MYGN) announced a particularly strong partnership deal for its lead drug, Flurizan. Flurizan is currently in late-stage testing as a treatment for Alzheimer's...

analysis/comments

Myriad's Flurizan Deal Is a Hedged Bet (at TheStreet.com)

yahoo.com     22-May-2008          

Myriad Genetics MYGN surprised investors early Thursday selling outside-the-U.S. rights to its Alzheimer's drug Flurizan -- mere weeks before late-stage data will offer more clues to the drug's approvability. Danish company Lundbeck will pay Myriad $100 million upfront...

analysis/comments

                   

Myriad Gets $100M Upfront in European Deal for Flurizan

tmcnet.com     22-May-2008          

250M Potential As its Flurizan product nears what could be a multi-billion dollar market in Alzheimer's disease, Myriad Genetics Inc. launched its global strategy by signing a commercialization deal in Europe with J. Lundbeck AS for $100 million upfront with a potential for $250 million. Myriad...

analysis/comments

Biotech Stocks: Drug stocks gain; Myriad climbs on drug-licensing deal

marketwatch.com     22-May-2008          

Drug stocks gain; Myriad climbs on Flurizan deal BOSTON (MarketWatch) -- Drug stocks gained Thursday as Myriad Genetics Inc. shares climbed on news that the company has signed a deal with Swedish drug conglomerate H. Lundbeck A/S for the European commercialization of its Alzheimer's drug...

analysis/comments

Biotech Stocks: Drug stocks gain; Myriad climbs on drug-licensing deal (at MarketWatch)

yahoo.com     22-May-2008          

Drug stocks gain; Myriad climbs on Flurizan deal BOSTON (MarketWatch) -- Drug stocks gained Thursday as Myriad Genetics Inc. shares climbed on news that the company has signed a deal with Swedish drug conglomerate H. Lundbeck A/S for the European commercialization of its Alzheimer's drug...

analysis/comments

                   

Lundbeck: Myriad Deal is a High Risk High Reward Strategy

redorbit.com     22-May-2008          

Posted on: Thursday, 22 May 2008, 11:53 CDT Lundbeck has acquired the European commercialization rights to Myriad's new Alzheimer's treatment, Flurizan. However, late stage failures are common in the Alzheimer's disease drug pipeline and, as such, Lundbeck is taking on a high risk investment;...

analysis/comments

Myriad licenses Alzheimer's drug to Lundbeck (at Reuters)

yahoo.com     22-May-2008          

LOS ANGELES, May 22 (Reuters) - Myriad Genetics Inc (MYGN.O: ) said on Thursday that Denmark's H Lundbeck A/S (LUN.CO: ) will acquire European rights to its experimental Alzheimer's disease drug Flurizan, but the deal will increase Myriad's quarterly loss. Lundbeck will pay Myriad an initial $100...

analysis/comments

UPDATE - Lundbeck buys European rights to Alzheimer's drug (at Reuters)

yahoo.com     22-May-2008          

By Gelu Sulugiuc COPENHAGEN, May 22 (Reuters) - Danish pharmaceutical group Lundbeck (LUN.CO: ) said on Thursday it had acquired the European rights to Myriad Genetics' Flurizan, an experimental Alzheimer's drug it hopes can become the company's next blockbuster. Lundbeck will pay Myriad (MYGN.O:...

analysis/comments

Myriad Genetics Sells Flurizan Licensing Rights (at TheStreet.com)

yahoo.com     22-May-2008          

Myriad Genetics MYGN said early Thursday that it sold rights outside the U.S. rights to its late-stage Alzheimer's drug Flurizan. The biotech company struck a deal worth as much as $350 million with Lundbeck A/S. The Danish company will pay Myriad $100 million upfront and up to $250 million in...

analysis/comments

Biotech Stocks: Drug stocks mixed; Myriad gains on Alzheimer's deal (at MarketWatch)

yahoo.com     22-May-2008          

Drug stocks mixed; Myriad climbs on Alzheimer's deal BOSTON (MarketWatch) -- Drug stocks were mixed in early action Thursday with shares of Myriad Genetics Inc. climbing on news that it has signed a deal with Swedish drug conglomerate H. Lundbeck A/S for the European commercialization of Myriad's...

analysis/comments

1 2 3 next